Frequent Genetic and Biochemical Alterations of the PI 3-K/AKT/PTEN Pathway in Head and Neck Squamous Cell Carcinoma
Overview
Authors
Affiliations
We investigated the status of the PI 3-kinase/AKT/PTEN signaling pathway in a series of 117 head and neck squamous cell carcinomas (HNSCC) in a search for molecular alterations in genes/proteins with potential prognostic value. For this purpose, PIK3CA and AKT2 gene amplification was assessed by multiplex and Quantitative Real-Time PCR. Protein expression of AKT, p-AKT, p110alpha and PTEN was determined by Western blot. PTEN allelic loss was evaluated by microsatellite analysis. PTEN-exon 5 was screened for point mutations by PCR-SSCP. Homozygous deletions were determined by multiplex PCR. PIK3CA gene was amplified in 43/117 (37%) fresh tumor samples, a frequency that did not differ from that found in archival premalignant tissues: 15/38 (39%); 12/40 (30%) fresh tumors harbored AKT2 gene amplification. AKT was found activated in 6/36 (17%) fresh tumor samples, when compared to their normal tissue counterparts. Of these 6 cases, 1 showed p110alpha overexpression and 5 displayed PTEN protein downregulation. Neither allelic loss (found in 11/77 informative cases) nor point mutations or homozygous deletions accounted for the reduced PTEN protein expression observed in our tumor series. The histologically normal mucosa of 4 patients displayed some of the molecular alterations analyzed. Dysregulation of the PI 3-K/AKT/PTEN pathway might contribute to early HNSCC tumorigenesis and might constitute a potential clinical target. Overall, 17/36 (47%) cases showed at least 1 of the molecular alterations studied here, which makes the PI 3-kinase-initiated signaling pathway one of the most frequently altered in HNSCC.
Levi L, Hikri E, Popovtzer A, Dayan A, Levi A, Bachar G J Clin Med. 2023; 12(4).
PMID: 36835812 PMC: 9967316. DOI: 10.3390/jcm12041277.
Influence of the Microbiome Metagenomics and Epigenomics on Gastric Cancer.
Mathebela P, Damane B, Mulaudzi T, Mkhize-Khwitshana Z, Gaudji G, Dlamini Z Int J Mol Sci. 2022; 23(22).
PMID: 36430229 PMC: 9693604. DOI: 10.3390/ijms232213750.
Bouyahya A, El Allam A, Aboulaghras S, Bakrim S, El Menyiy N, Alshahrani M Cancers (Basel). 2022; 14(22).
PMID: 36428613 PMC: 9688668. DOI: 10.3390/cancers14225520.
Zaryouh H, De Pauw I, Baysal H, Pauwels P, Peeters M, Vermorken J Front Oncol. 2021; 11:697967.
PMID: 34568028 PMC: 8462273. DOI: 10.3389/fonc.2021.697967.
Bellei B, Caputo S, Migliano E, Lopez G, Marcaccini V, Cota C Biomedicines. 2021; 9(6).
PMID: 34073987 PMC: 8225214. DOI: 10.3390/biomedicines9060597.